10x Genomics’s (NASDAQ:TXG) Q3: Strong Sales, Stock Jumps 13.1%

Biotech institution 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results beating Wall Street’s gross expectations , but income fell by 1.7% twelvemonth connected twelvemonth to $149 million. On apical of that, adjacent quarter’s gross guidance ($156 cardinal astatine the midpoint) was amazingly bully and 3.5% supra what analysts were expecting. Its GAAP nonaccomplishment of $0.22 per stock was 22.3% supra analysts’ statement estimates.

Is present the clip to bargain 10x Genomics? Find retired successful our afloat probe report.

• Revenue: $149 cardinal vs expert estimates of $142.4 cardinal (1.7% year-on-year decline, 4.6% beat)

• EPS (GAAP): -$0.22 vs expert estimates of -$0.28 (22.3% beat)

• Revenue Guidance for Q4 CY2025 is $156 cardinal astatine the midpoint, supra expert estimates of $150.7 million

• Operating Margin: -21.6%, up from -27.4% successful the aforesaid 4th past year

• Market Capitalization: $1.68 billion

"Our squad delivered a coagulated 3rd quarter, and we proceed to spot notable enthusiasm for our azygous compartment and spatial products," said Serge Saxonov, Co-founder and CEO of 10x Genomics.

Founded successful 2012 by scientists seeking to flooded limitations successful accepted biologic probe methods, 10x Genomics (NASDAQ:TXG) develops instruments, consumables, and bundle that alteration researchers to analyse biologic systems astatine single-cell solution and spatial context.

Reviewing a company’s semipermanent income show reveals insights into its quality. Any concern tin person short-term success, but a top-tier 1 grows for years. Over the past 5 years, 10x Genomics grew its income astatine an awesome 19.6% compounded yearly maturation rate. Its maturation bushed the mean healthcare institution and shows its offerings resonate with customers.

We astatine StockStory spot the astir accent connected semipermanent growth, but wrong healthcare, a half-decade humanities presumption whitethorn miss caller innovations oregon disruptive manufacture trends. 10x Genomics’s caller show shows its request has slowed importantly arsenic its annualized gross maturation of 4.2% implicit the past 2 years was good beneath its five-year trend.

We tin excavation further into the company’s gross dynamics by analyzing its astir important segment, Consumables. Over the past 2 years, 10x Genomics’s Consumables gross (recurring orders) was flat. This conception has lagged the company’s wide sales.

This quarter, 10x Genomics’s gross fell by 1.7% twelvemonth connected twelvemonth to $149 cardinal but bushed Wall Street’s estimates by 4.6%. Company absorption is presently guiding for a 5.5% year-on-year diminution successful income adjacent quarter.